• 1

    Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277300. Erratum in: CA Cancer J Clin 2011;61:133–134.

  • 2

    National Cancer Institute. Surveillance Epidemiology and End Results. 2008. Available at: http://seer.cancer.gov/statfacts/html/melan.html#ref11. Accessed November 29, 2011.

    • Search Google Scholar
    • Export Citation
  • 3

    Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003;349:22332240.

  • 4

    Rigel DS, Rivers JK, Kopf AW. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989;63:386389.

  • 5

    Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatol Surg 2006;32:481492.

  • 6

    Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:9981012.

  • 7

    Balch CM, Gershenwald JE, Soong SJ. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:61996206.

  • 8

    Edge SB, Carducci M, Byrd DR, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer-Verlag New York, LLC; 2009.

  • 9

    Barnhill RL, Katzen J, Spatz A. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005;32:268273.

    • Search Google Scholar
    • Export Citation
  • 10

    Azzola MF, Shaw HM, Thompson JF. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003;97:14881498.

    • Search Google Scholar
    • Export Citation
  • 11

    Francken AB, Shaw HM, Thompson JF. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004;11:426433.

    • Search Google Scholar
    • Export Citation
  • 12

    Gimotty PA, Elder DE, Fraker DL. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25:11291134.

    • Search Google Scholar
    • Export Citation
  • 13

    Paek SC, Griffith KA, Johnson TM. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007;109:100108.

    • Search Google Scholar
    • Export Citation
  • 14

    Sondak VK, Taylor JM, Sabel MS. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247258.

    • Search Google Scholar
    • Export Citation
  • 15

    Sober AJ, Chuang TY, Duvic M. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001;45:579586.

  • 16

    George E, McClain SE, Slingluff CL. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol 2009;36:425432.

    • Search Google Scholar
    • Export Citation
  • 17

    Busam KJ. Desmoplastic melanoma. Clin Lab Med 2011;31:321330.

  • 18

    Murali R, Shaw HM, Lai K. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer 2010;116:41304138.

  • 19

    Raskin L, Ludgate M, Iyer RK. Copy number variations and clinical outcome in atypical spitz tumors. Am J Surg Pathol 2011;35:243252.

  • 20

    Balch CM, Soong SJ, Gershenwald JE. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:36223634.

    • Search Google Scholar
    • Export Citation
  • 21

    Neuman HB, Patel A, Ishill N. A single-institution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol 2008;15:20342041.

    • Search Google Scholar
    • Export Citation
  • 22

    Cascinelli N, Belli F, Santinami M. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000;7:469474.

    • Search Google Scholar
    • Export Citation
  • 23

    Buzaid AC, Sandler AB, Mani S. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993;11:638643.

  • 24

    Wang TS, Johnson TM, Cascade PN. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004;51:399405.

    • Search Google Scholar
    • Export Citation
  • 25

    Yancovitz M, Finelt N, Warycha MA. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007;110:11071114.

    • Search Google Scholar
    • Export Citation
  • 26

    Aloia TA, Gershenwald JE, Andtbacka RH. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006;24:28582865.

    • Search Google Scholar
    • Export Citation
  • 27

    Gold JS, Jaques DP, Busam KJ. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2007;14:21332140.

    • Search Google Scholar
    • Export Citation
  • 28

    Miranda EP, Gertner M, Wall J. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004;139:831836; discussion 836–837.

    • Search Google Scholar
    • Export Citation
  • 29

    Pandalai PK, Dominguez FJ, Michaelson J, Tanabe KK. Clinical value of radiographic staging in patients diagnosed with AJCC stage III melanoma. Ann Surg Oncol 2011;18:506513.

    • Search Google Scholar
    • Export Citation
  • 30

    Buzaid AC, Tinoco L, Ross MI. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995;13:21042108.

    • Search Google Scholar
    • Export Citation
  • 31

    Johnson TM, Fader DJ, Chang AE. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997;4:396402.

    • Search Google Scholar
    • Export Citation
  • 32

    Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997;4:252258.

  • 33

    Clark PB, Soo V, Kraas J. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006;141:284288.

    • Search Google Scholar
    • Export Citation
  • 34

    Maubec E, Lumbroso J, Masson F. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res 2007;17:147154.

    • Search Google Scholar
    • Export Citation
  • 35

    Wagner JD, Schauwecker D, Davidson D. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104:570579.

    • Search Google Scholar
    • Export Citation
  • 36

    Brady MS, Akhurst T, Spanknebel K. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006;13:525532.

    • Search Google Scholar
    • Export Citation
  • 37

    Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438441.

  • 38

    Veronesi U, Cascinelli N, Adamus J. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:11591162.

    • Search Google Scholar
    • Export Citation
  • 39

    Balch CM, Soong SJ, Smith T. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101108.

    • Search Google Scholar
    • Export Citation
  • 40

    Balch CM, Urist MM, Karakousis CP. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262267; discussion 267–269.

    • Search Google Scholar
    • Export Citation
  • 41

    Cohn-Cedermark G, Rutqvist LE, Andersson R. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000;89:14951501.

    • Search Google Scholar
    • Export Citation
  • 42

    Khayat D, Rixe O, Martin G. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003;97:19411946.

    • Search Google Scholar
    • Export Citation
  • 43

    Thomas JM, Newton-Bishop J, A’Hern R. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757766.

  • 44

    Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003;46:419426.

    • Search Google Scholar
    • Export Citation
  • 45

    Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol 1997;37:758764.

    • Search Google Scholar
    • Export Citation
  • 46

    Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol 1997;37:236245.

    • Search Google Scholar
    • Export Citation
  • 47

    Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008;34:147151.

  • 48

    Naylor MF, Crowson N, Kuwahara R. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003;149(Suppl 66):6670.

  • 49

    Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004;29:1521.

    • Search Google Scholar
    • Export Citation
  • 50

    Spenny ML, Walford J, Werchniak AE. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007;79:149152.

    • Search Google Scholar
    • Export Citation
  • 51

    Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol 2008;144:943945.

    • Search Google Scholar
    • Export Citation
  • 52

    Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002;146:10421046.

    • Search Google Scholar
    • Export Citation
  • 53

    Johnson TM, Sondak VK, Bichakjian CK, Sabel MS. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol 2006;54:1927.

    • Search Google Scholar
    • Export Citation
  • 54

    Morton DL, Cochran AJ, Thompson JF. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302311; discussion 311–303.

    • Search Google Scholar
    • Export Citation
  • 55

    Morton DL, Thompson JF, Cochran AJ. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:13071317.

  • 56

    Thompson JF, Shaw HM. Sentinel node mapping for melanoma: results of trials and current applications. Surg Oncol Clin N Am 2007;16:3554.

  • 57

    Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw 2009;7:308317.

  • 58

    Wright BE, Scheri RP, Ye X. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 2008;143:892899; discussion 899–900.

    • Search Google Scholar
    • Export Citation
  • 59

    Bleicher RJ, Essner R, Foshag LJ. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003;21:13261331.

  • 60

    Ranieri JM, Wagner JD, Wenck S. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006;13:927932.

  • 61

    Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006;13:302309.

  • 62

    Ferrone CR, Panageas KS, Busam K. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002;9:637645.

    • Search Google Scholar
    • Export Citation
  • 63

    Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000;7:160165.

    • Search Google Scholar
    • Export Citation
  • 64

    Gutzmer R, Satzger I, Thoms KM. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 2008;6:198203.

    • Search Google Scholar
    • Export Citation
  • 65

    Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: is there an association with subclinical sentinel lymph node metastasis? Am J Dermatopathol 2003;25:371376.

    • Search Google Scholar
    • Export Citation
  • 66

    Morris KT, Busam KJ, Bero S. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 2008;15:316322.

    • Search Google Scholar
    • Export Citation
  • 67

    Cascinelli N, Bombardieri E, Bufalino R. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006;24:44644471.

    • Search Google Scholar
    • Export Citation
  • 68

    Lee JH, Essner R, Torisu-Itakura H. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004;22:36773684.

    • Search Google Scholar
    • Export Citation
  • 69

    Coit DG. Extent of groin dissection for melanoma. Surg Clin North Am 1992;1:271280.

  • 70

    Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989;124:162166.

  • 71

    Shen P, Conforti AM, Essner R. Is the node of Cloquet the sentinel node for the iliac/obturator node group? Cancer J 2000;6:9397.

  • 72

    Cascinelli N, Belli F, MacKie RM. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866869.

    • Search Google Scholar
    • Export Citation
  • 73

    Grob JJ, Dreno B, de la Salmoniere P. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:19051910.

    • Search Google Scholar
    • Export Citation
  • 74

    Pehamberger H, Soyer HP, Steiner A. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:14251429.

    • Search Google Scholar
    • Export Citation
  • 75

    Hancock BW, Wheatley K, Harris S. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:5361.

    • Search Google Scholar
    • Export Citation
  • 76

    Eggermont AM, Suciu S, MacKie R. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005;366:11891196.

    • Search Google Scholar
    • Export Citation
  • 77

    Kirkwood JM, Strawderman MH, Ernstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:717.

    • Search Google Scholar
    • Export Citation
  • 78

    Kirkwood JM, Ibrahim JG, Sondak VK. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:24442458.

    • Search Google Scholar
    • Export Citation
  • 79

    Eggermont AM, Suciu S, Ruka W. EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 9004.

    • Search Google Scholar
    • Export Citation
  • 80

    Gogas H, Ioannovich J, Dafni U. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709718.

    • Search Google Scholar
    • Export Citation
  • 81

    Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002;20:18181825.

    • Search Google Scholar
    • Export Citation
  • 82

    Kirkwood JM, Manola J, Ibrahim J. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:16701677.

    • Search Google Scholar
    • Export Citation
  • 83

    Verma S, Quirt I, McCready D. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:14311442.

    • Search Google Scholar
    • Export Citation
  • 84

    Eggermont AM, Suciu S, Santinami M. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117126.

    • Search Google Scholar
    • Export Citation
  • 85

    Eggermont AM, Suciu S, Testori A. Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 9007.

    • Search Google Scholar
    • Export Citation
  • 86

    Chen JY, Hruby G, Scolyer RA. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008;113:27702778.

  • 87

    Agrawal S, Kane JM III, Guadagnolo BA. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009;115:58365844.

    • Search Google Scholar
    • Export Citation
  • 88

    Henderson MA, Burmeister B, Thompson JF. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01) [abstract]. J Clin Oncol 2009;27(Suppl 18):Abstract LBA 9084.

    • Search Google Scholar
    • Export Citation
  • 89

    Beadle BM, Guadagnolo BA, Ballo MT. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2009;73:13761382.

    • Search Google Scholar
    • Export Citation
  • 90

    Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006;66:10511055.

    • Search Google Scholar
    • Export Citation
  • 91

    Sause WT, Cooper JS, Rush S. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991;20:429432.

    • Search Google Scholar
    • Export Citation
  • 92

    Yao KA, Hsueh EC, Essner R. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg 2003;238:743747.

    • Search Google Scholar
    • Export Citation
  • 93

    Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol 2003;4:359364.

    • Search Google Scholar
    • Export Citation
  • 94

    Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127136.

    • Search Google Scholar
    • Export Citation
  • 95

    Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004;88:13.

    • Search Google Scholar
    • Export Citation
  • 96

    Beasley GM, Caudle A, Petersen RP. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009;208:706715; discussion 715–707.

    • Search Google Scholar
    • Export Citation
  • 97

    Boesch CE, Meyer T, Waschke L. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. Int J Hyperthermia 2010;26:1620.

    • Search Google Scholar
    • Export Citation
  • 98

    Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985990.

    • Search Google Scholar
    • Export Citation
  • 99

    Wolf IH, Richtig E, Kopera D, Kerl H. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg 2004;30:244247.

    • Search Google Scholar
    • Export Citation
  • 100

    Turza K, Dengel LT, Harris RC. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 2010;37:9498.

    • Search Google Scholar
    • Export Citation
  • 101

    Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:2134.

    • Search Google Scholar
    • Export Citation
  • 102

    Middleton MR, Grob JJ, Aaronson N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158166.

    • Search Google Scholar
    • Export Citation
  • 103

    Smith FO, Downey SG, Klapper JA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:56105618.

    • Search Google Scholar
    • Export Citation
  • 104

    Rosenberg SA, Yang JC, Topalian SL. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907913.

    • Search Google Scholar
    • Export Citation
  • 105

    Atkins MB, Lotze MT, Dutcher JP. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:21052116.

    • Search Google Scholar
    • Export Citation
  • 106

    Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6(Suppl 1):S1114.

    • Search Google Scholar
    • Export Citation
  • 107

    Flaherty KT, Lee SJ, Schuchter LM. Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 8511.

    • Search Google Scholar
    • Export Citation
  • 108

    Hauschild A, Agarwala SS, Trefzer U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:28232830.

    • Search Google Scholar
    • Export Citation
  • 109

    Agarwala SS, Keilholz U, Hogg D. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J Clin Oncol 2007;25(Suppl 18):Abstract 8510.

    • Search Google Scholar
    • Export Citation
  • 110

    Rao RD, Holtan SG, Ingle JN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 2006;106:375382.

    • Search Google Scholar
    • Export Citation
  • 111

    Papadopoulos NE, Bedikian A, Ring S. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol 2009;32:509514.

    • Search Google Scholar
    • Export Citation
  • 112

    Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748759.

    • Search Google Scholar
    • Export Citation
  • 113

    Houghton AN, Coit DG, Daud A. Melanoma. J Natl Compr Canc Netw 2006;4:666684.

  • 114

    Hodi FS, O’Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711723.

  • 115

    Robert C, Thomas L, Bondarenko I. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:25172526.

  • 116

    Flaherty KT, Puzanov I, Kim KB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809819.

  • 117

    Chapman PB, Hauschild A, Robert C. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:25072516.

  • 118

    Legha SS, Ring S, Bedikian A. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7:827835.

    • Search Google Scholar
    • Export Citation
  • 119

    Legha SS, Ring S, Eton O. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:17521759.

    • Search Google Scholar
    • Export Citation
  • 120

    O’Day SJ, Boasberg PD, Piro L. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002;8:27752781.

    • Search Google Scholar
    • Export Citation
  • 121

    Eton O, Legha SS, Bedikian AY. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:20452052.

    • Search Google Scholar
    • Export Citation
  • 122

    Atkins M, Hsu J, Lee S. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:57485754.

    • Search Google Scholar
    • Export Citation
  • 123

    Bajetta E, Del Vecchio M, Nova P. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006;17:571577.

    • Search Google Scholar
    • Export Citation
  • 124

    Keilholz U, Punt CJ, Gore M. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005;23:67476755.

    • Search Google Scholar
    • Export Citation
  • 125

    Ridolfi R, Chiarion-Sileni V, Guida M. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:16001607.

    • Search Google Scholar
    • Export Citation
  • 126

    Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007;25:54265434.

    • Search Google Scholar
    • Export Citation
  • 127

    Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 1988;61:243246.

    • Search Google Scholar
    • Export Citation
  • 128

    Olivier KR, Schild SE, Morris CG. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 2007;110:17911795.

    • Search Google Scholar
    • Export Citation
  • 129

    Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 1985;11:18371839.

    • Search Google Scholar
    • Export Citation
  • 130

    Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999;44:607618.

    • Search Google Scholar
    • Export Citation
  • 131

    Ferrone CR, Ben Porat L, Panageas KS. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:16471654.

    • Search Google Scholar
    • Export Citation
  • 132

    Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990;212:173177.

  • 133

    Basseres N, Grob JJ, Richard MA. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995;191:199203.

    • Search Google Scholar
    • Export Citation
  • 134

    Romano E, Scordo M, Dusza SW. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010;28:30423047.

    • Search Google Scholar
    • Export Citation
  • 135

    Fawzy FI, Fawzy NW, Hyun CS. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993;50:681689.

    • Search Google Scholar
    • Export Citation
  • 136

    Gutman M, Cnaan A, Inbar M. Are malignant melanoma patients at higher risk for a second cancer? Cancer 1991;68:660665.

  • 137

    Kang S, Barnhill RL, Mihm MC Jr, Sober AJ. Multiple primary cutaneous melanomas. Cancer 1992;70:19111916.

  • 138

    Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007;357:22772284.

  • 139

    Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 2009;16:571577.

    • Search Google Scholar
    • Export Citation
  • 140

    Weiss M, Loprinzi CL, Creagan ET. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:17031705.

    • Search Google Scholar
    • Export Citation
  • 141

    Fazel R, Krumholz HM, Wang Y. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009;361:849857.

  • 142

    Rhodes AR. Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer? Cancer 1995;75:613636.

    • Search Google Scholar
    • Export Citation
  • 143

    Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29:257263.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 432 289 25
PDF Downloads 93 68 6
EPUB Downloads 0 0 0